Kamilė Čerlinskaitė-Bajorė

Kamilė Čerlinskaitė-Bajorė

Auto-generated profile, based on publicly available information

Kamilė Čerlinskaitė-Bajorė

Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University , Vilnius

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in European Journal of Heart Failure
Verified
Journal Article
Open access
KČKamilė Čerlinskaitė-Bajorė
Kamilė Čerlinskaitė-Bajorė
CLCarolyn S.P. Lam
Carolyn S.P. Lam
KSKaren Sliwa
Karen Sliwa
MAMarianna Adamo
Marianna Adamo
JMJozine M. Ter Maaten
Jozine M. Ter Maaten
JČJelena Čelutkienė
Jelena Čelutkienė
Aims: The aim of this study was to evaluate efficacy and safety of rapid up-titration of guideline-directed medical therapies (GDMT) in men and women hospitalized for acute heart failure (AHF). Methods and results: In STRONG-HF, AHF patients were randomized just prior to discharge to either usual care (UC) or a high-intensity care (HIC) strategy of GDMT up-titration. In these analyses, we compared the implementation, efficacy, and safety of the HIC strategy between men and women. In the randomized AHF population, 416/1078 (39%) were women. By day 90, a higher proportion of both sexes in the HIC group had been up-titrated to full doses of GDMT compared to UC. Overall, there were no differences in the primary endpoint between the sexes. The primary endpoint, 180-day heart failure readmission or death, occurred in 15.8% HIC women versus 23.5% women in the UC group (adjusted hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.40–1.13) and in 14.9% HIC men versus 23.5% UC men (adjusted HR 0.57, 95% CI 0.38–0.88) (adjusted interaction p = 0.65). There was no significant treatment-by-sex interaction in quality-of-life improvement or in adverse events, including serious or fatal adverse events. Conclusion: The results of the current analyses suggest that a rapid up-titration of GDMT immediately after an AHF hospitalization can and should be implemented similarly in men and women, as it results in reduction of 180-day all-cause death or heart failure readmission, quality-of-life improvement in both men and women with a similar safety profile.

1 January 2018 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
KČKamilė Čerlinskaitė
Kamilė Čerlinskaitė
TJTuija Javanainen
Tuija Javanainen
RCRaphaël Cinotti
Raphaël Cinotti
AMAlexandre Mebazaa
Alexandre Mebazaa
ONon behalf of the Global Research on Acute Conditions Team (GREAT) Network
on behalf of the Global Research on Acute Conditions Team (GREAT) Network
Korean Circulation Journal 대한심장학회지 순환기 Čerlinskaitė K, et al. Korean Circ J. 2018 Jun;48(6):463-480. https://doi.org/10.4070/kcj.2018.0125

1 April 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
JČJelena Čelutkienė
Jelena Čelutkienė
KČKamilė Čerlinskaitė-Bajorė
Kamilė Čerlinskaitė-Bajorė
GCGad Cotter
Gad Cotter
CEChristopher Edwards
Christopher Edwards
MAMarianna Adamo
Marianna Adamo
BDBeth Davison
Beth Davison
BACKGROUND: This analysis provides details on baseline and changes in quality of life (QoL) and its components as measured by EQ-5D-5L questionnaire, as well as association with objective outcomes, applying high-intensity heart failure (HF) care in patients with acute HF. METHODS: In STRONG-HF trial (Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies) patients with acute HF were randomized just before discharge to either usual care or a high-intensity care strategy of guideline-directed medical therapy up-titration. Patients ranked their state of health on the EQ-5D visual analog scale score ranging from 0 (the worst imaginable health) to 100 (the best imaginable health) at baseline and at 90 days follow-up. RESULTS: In 1072 patients with acute HF with available assessment of QoL (539/533 patients assigned high-intensity care/usual care) the mean baseline EQ-visual analog scale score was 59.2 (SD, 15.1) with no difference between the treatment groups. Patients with lower baseline EQ-visual analog scale (meaning worse QoL) were more likely to be women, self-reported Black and non-European ( P <0.001). The strongest independent predictors of a greater improvement in QoL were younger age ( P <0.001), no HF hospitalization in the previous year ( P <0.001), lower NYHA class before hospital admission ( P <0.001) and high-intensity care treatment (mean difference, 4.2 [95% CI, 2.5–5.8]; P <0.001). No statistically significant heterogeneity in the benefits of high-intensity care was seen across patient subgroups of different ages, with left ventricular ejection fraction above or below 40%, NT-proBNP (N-terminal pro-B-type natriuretic peptide) and systolic blood pressure above or below the median value. The treatment effect on the primary end point did not vary significantly across baseline EQ-visual analog scale ( P interaction =0.87). CONCLUSIONS: Early up-titration of guideline-directed medical therapy significantly improves all dimensions of QoL in patients with HF and improves prognosis regardless of baseline self-assessed health status. The likelihood of achieving optimal doses of HF medications does not depend on baseline QoL. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03412201.

10 June 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
KČKamilė Čerlinskaitė
Kamilė Čerlinskaitė
AMAlexandre Mebazaa
Alexandre Mebazaa
RCRaphaël Cinotti
Raphaël Cinotti
MMMichael Matthay
Michael Matthay
DWDesiree N. Wussler
Desiree N. Wussler
GNGreat Network
Great Network
Aims Readmission and mortality are the most common and often combined endpoints in acute heart failure (AHF) trials, but an association between these two outcomes is poorly investigated. The aim of this study was to determine whether unplanned readmission is associated with a greater subsequent risk of death in patients with acute dyspnoea due to cardiac and non-cardiac causes. Methods and results Derivation cohort (1371 patients from the LEDA study) and validation cohort (1986 patients from the BASEL V study) included acute dyspnoea patients admitted to the emergency department. Cox regression analysis was used to determine the association of 6 month readmission and the risk of 1 year all-cause mortality in AHF and non-AHF patients and those readmitted due to cardiovascular and non-cardiovascular causes. In the derivation cohort, 666 (49%) of patients were readmitted at 6 months and 282 (21%) died within 1 year. Six month readmission was associated with an increased 1 year mortality risk in both the derivation cohort [adjusted hazard ratio (aHR) 3.0 (95% confidence interval, CI 2.2–4.0), P < 0.001] and the validation cohort (aHR 1.8, 95% CI 1.4–2.2, P < 0.001). The significant association was similarly observed in AHF (aHR 3.2, 95% CI 2.1–4.9, P < 0.001) and other causes of acute dyspnoea (aHR 2.9, 95% CI 1.9–4.5, P < 0.001), and it did not depend on the aetiology [aHR 2.2, 95% CI 1.6–3.1 for cardiovascular readmissions; aHR 4.1, 95% CI 2.9–5.7 for non-cardiovascular readmissions (P < 0.001 for both)] or timing of readmission. Conclusion​s Our study demonstrated a long-lasting detrimental association between readmission and death in AHF and non-AHF patients with acute dyspnoea. These patients should be considered ‘vulnerable patients’ that require personalized follow-up for an extended period.

19 February 2024 in Structural Heart
Verified
Journal Article
Open access
VBVilhelmas Bajoras
Vilhelmas Bajoras
IWIvan Wong
Ivan Wong
XWXi Wang
Xi Wang
KČKamilė Čerlinskaitė-Bajorė
Kamilė Čerlinskaitė-Bajorė
GBGintautas Bieliauskas
Gintautas Bieliauskas
OBOle De Backer
Ole De Backer

27 November 2025 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JBJolie Bruno
Jolie Bruno
ADAziz Daghmouri
Aziz Daghmouri
AAAyu Asakage
Ayu Asakage
CCCamille Chenevier-Gobeaux
Camille Chenevier-Gobeaux
KČKamilė Čerlinskaitė-Bajorė
Kamilė Čerlinskaitė-Bajorė
SIShiro Ishihara
Shiro Ishihara
Jolie Bruno, M.D., Aziz Daghmouri, M.D., Ayu Asakage, M.D., Camille Gobeaux, M.D., Kamilė Čerlinskaitė-Bajorė, M.D., Jelena Čelutkienė, M.D., Ph.D., Naoki Sato, M.D., Ph.D., Koji Takagi, M.D., Alexandre Mebazaa, M.D., Ph.D., Benjamin Deniau, M.D., Ph.D., and Shiro Ishihara, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0232